Insider Selling: Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells 45,698 Shares of Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) major shareholder Aron R. English sold 45,698 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.03, for a total transaction of $321,256.94. Following the sale, the insider now owns 1,662,574 shares of the company's stock, valued at $11,687,895.22. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Price Performance

Shares of LFCR stock traded up $0.01 during mid-day trading on Monday, hitting $6.98. The company had a trading volume of 317,111 shares, compared to its average volume of 235,089. The company has a market capitalization of $258.43 million, a P/E ratio of -12.46 and a beta of 0.65. The stock's 50 day moving average price is $6.41 and its 200-day moving average price is $6.51. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $35.15 million for the quarter, compared to the consensus estimate of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Lifecore Biomedical by 1,839.7% in the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock valued at $25,000 after purchasing an additional 3,385 shares during the last quarter. Hurley Capital LLC acquired a new stake in Lifecore Biomedical in the 1st quarter valued at $35,000. ARS Investment Partners LLC purchased a new position in shares of Lifecore Biomedical in the fourth quarter worth about $74,000. Prudential Financial Inc. purchased a new stake in Lifecore Biomedical during the 4th quarter valued at about $95,000. Finally, Wells Fargo & Company MN grew its stake in Lifecore Biomedical by 29.0% during the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock valued at $99,000 after acquiring an additional 3,012 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.